![](https://www.inotrem.com/wp-content/uploads/2019/09/septic-shock-treatment.gif)
Inotrem Announces Fast Track Designation Granted by U.S. FDA to Nangibotide development program for the Treatment of Septic Shock
Paris, September 3rd. 2019. Inotrem S.A., a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes, announced today that the U.S. Food and